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Background According to treatment guidelines in spasticity
management, botulinum toxin injections should be offered as a
treatment option for focal spasticity. In severe combined upper and
lower limb or in multifocal spasticity, doses required to improve
goal achievement and fulﬁl patients’ needs can result in total doses
exceeding those currently approved, which are in France 360 U for
onabotulinumtoxin A 400 U for incobotulinumtoxin A and 1500 U
for abobotulinumtoxin A. Therefore, the challenges of treating
patients with multifocal spasticity with botulinum toxin type A
increase with the number of disabling patterns. Physicians may
need to prioritize treating patterns with a high impact on overall
goal achievement.
Methods TOWER is a prospective, open-label, non-randomized,
single-arm,multicenter, dose-titration phase III studywith the aim
to investigate the safety and efﬁcacy of incobotulinumtoxinA in the
treatment of spasticity in patients who are deemed to require total
body doses of up to 800 U. The study employs a dose-titration
approach over three injection cycles with a ﬁxed total body dose of
400 U of incobotulinumtoxinA for injection cycle 1, 600 U for cycle
2 and 800 U for cycle 3 with a maximum dose per limb of 400 U in
cycle 1 and 600 U in cycle 2 and 3.
Results One hundred and ﬁfty-ﬁve patients aged 18–80 years
with spasticity of the upper and lower limb of the same body side
due to cerebral causes and having to deemed by the investigator to
require total body doses of incobotulinumtoxinA 800 U during the
course of the trial, participate at 30 study sites in Canada, France,
Germany, Italy, Norway, Portugal, Spain, and the USA. Results of
the cycle with 800 U show that the number of patterns treated is
higher with this cycle than at the cycle with 600 U. The same
results are found between the cycle with 600 U and 400 U.
Conclusion Many physicians would like to be allowed greater
dosing ﬂexibility to improve treatment satisfaction for a subset of
patients with post-stroke spasticity. Results from TOWER study
show that the treated number of patterns is higher with this cycle
than the cycle with 600 U. The same results are found between the
cycle with 600 U and 400 U.
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Introduction Botulinum toxin (BT) injected into the skeletal
muscle is the reference treatment of focal spasticity. It induces
blockade of the presynaptic release of acetylcholine causing a
decrease in muscle contraction. Three kinds of general complica-
tions are reported: ﬂu-like syndrome, fatigue and generalised
botulism. Their physiopathological mechanisms are not well
known, neither is the mechanism of BT diffusion. Along with this,
there is evidence of retrograde transport of the toxin via the neuron
since authors found the toxin, injected in peripheral muscle, in the
central nervous system. Moreover, acetylcholine is a neurotrans-
mitter in common for the sensorimotor system and the vegetative
system. This retrograde transport is the cause of a motor effect on
adjacentmuscles to the injectedmuscle. However, we do not know
the impact on the autonomic nervous system of the central
location of the toxin.
Objective Test the hypothesis of cardiovascular autonomic
effects of BT injected into the peripheral muscle in a population
of stroke patients who need spasticity focal treatment.
Material and methods Twenty chronic hemiparetic patients will
be tested. Our experimental setting includes: spontaneous
baroreﬂex study, spectral analysis of sinusal variability, Finapres
recording of heart rate and blood pressure during Ewing
maneuvers, sudoral function with SUDOSCAN. We take these
measures the day of injection, then 6 weeks later, which is the peak
of TB muscular efﬁciency and 6 months later.
Results Preliminary results on 5 spastic hemiparetic patients
(mean age = 46,6 years old; delay time from stroke = 3,7 years)
evaluated the day of injection and 6 weeks later found signiﬁcant
higher HR and BP at rest, without signiﬁcant differences of sinusal
variability nor Ewing score (baroreﬂex study analysis in process).
Discussion This pilot study is the ﬁrst onewhich analyses the link
between autonomic system and BT injected in the skeletal muscle
in the context of focal treatment of spasticity in a population of
stroke patients.
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